Clinical trial NCT00179660: Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
Official title: A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) In Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non-Hodgkins Lymphoma
Keywords: celgene
cc-5013
CC5013
NHL
Non-Hodgkins Lymphoma
Revlimid
Lead sponsor: Celgene
Sponsor class: INDUSTRY
Collaborators: name: Prologue Research International
First posted: 2005-09-16
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.


Eligibility criteria: Inclusion Criteria:

1. Understand and voluntarily sign an informed consent form.
2. Age greater than or equal to 18 years at the time of signing the informed consent form
3. Able to adhere to the study visit schedule and other protocol requirements
4. Biopsy-proven non-Hodgkin's lymphoma
5. Aggressive lymphoma, the following histologies are acceptable: Follicular center lymphoma, grade 3, Diffuse large cell, Mantle cell, Transformed
6. Relapsed or refractory to previous therapy for lymphoma. Patients must have received at least one prior treatment regimen such as radiation, immunotherapy, chemotherapy, or radioimmunotherapy, and be ineligible or unwilling to undergo an autologous stem cell transplant. There is no limit on the number of prior therapies.
7. Patients must have measurable disease on cross sectional imaging that is at least 2 cm in the longest diameter.
8. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
9. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.

Exclusion Criteria:

1. Any of the following laboratory abnormalities:

   1. Absolute neutrophil count (ANC) \<1,500 cells/mm\^3 (1.5 x 10\^9/L)
   2. Platelet count \<100,000/mm\^3 (100 x 10\^9/L)
   3. Serum creatinine \>2.5 mg/dL (221 mmol/L)
   4. Serum aspartate transaminase (AST) or alanine transaminase (ALT) \>5.0 x upper limit of normal (ULN)
   5. Serum total bilirubin \>2.0 mg/dL (34 mmol/L)
2. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
3. All patients with central nervous system (CNS) disease with the exception of those patients whose CNS disease has been treated with chemotherapy, radiotherapy or surgery and remains asymptomatic, with no active CNS disease, as shown by lumbar puncture, computed tomography (CT) scan or magnetic resonance imaging (MRI), for at least 6 months.
4. Prior history of malignancies other than non-Hodgkin's lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for \> or equal to 1 year
5. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
6. Known positive for human immunodeficiency virus (HIV)
7. Pregnant or lactating females
8. Prior \> or equal to grade 3 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) allergic reaction/hypersensitivity to thalidomide
9. Prior \> or equal to grade 3 NCI CTCAE rash or any desquamating (blistering) rash while taking thalidomide
10. Prior use of lenalidomide
11. Use of any standard or experimental anti-cancer drug therapy within 28 days of day 1 of study drug therapy
12. Known active Hepatitis C

Primary outcomes:
measure: Percentage of Participants With Response
timeFrame: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
Secondary outcomes:
measure: Percentage of Participants With Tumor Control
timeFrame: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
measure: Duration of Response
timeFrame: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
measure: Duration of Tumor Control
timeFrame: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
measure: Progression-free Survival
timeFrame: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
measure: Number of Participants With Adverse Events (AEs)
timeFrame: From the start of study drug through 30 days after the last dose of study drug. Maximum time on study drug was 15.2 months.
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic Scottsdale
state: Arizona
city: Fountain Valley
country: United States
facility: Pacific Coast Hematology/Oncology Medical Group, Onc.
state: California
city: Sacramento
country: United States
facility: UC David Cancer Center
state: California
city: Miami
country: United States
facility: Sylvester Cancer CenterUniversity Of Miami
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Omaha
country: United States
facility: University of Nebraska
state: Nebraska
city: Bronx
country: United States
facility: New York Medical Center, MBCCOP
state: New York
city: La Crosse
country: United States
facility: Gunderson Clinic, Ltd
state: Wisconsin
Study officials:
References:
citation: Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008 Oct 20;26(30):4952-7. doi: 10.1200/JCO.2007.15.3429. Epub 2008 Jul 7.